

Supplementary Table 1. Correlations between changes in plasma PAI-1 and those in clinical parameters from baseline to 12 weeks after treatment with empagliflozin in 31 patients with type 2 diabetes

Variable	<u>Changes in PAI-1 (ng/ml)</u>	
	r	P value
Changes in body weight (Kg)	0.4426	0.0162
Changes in BMI	0.4412	0.0166
Changes in WC (cm)	0.2373	0.2241
Changes in VFA (cm ²)	0.1127	0.5605
Changes in FPG (mg/dl)	-0.1755	0.3625
Changes in HbA1c (%)	-0.4402	0.0169
Changes in LDL cholesterol (mg/dl)	-0.1613	0.3944
Changes in Triglyceride (mg/dl)*	0.1508	0.4349
Changes in HDL-cholesterol (mg/dl)	-0.06603	0.7288
Changes in RLP-C (mg/dl)*	0.4370	0.0201
Changes in ALT (U/L)	-0.09992	0.6061
Changes in GGT (U/L)	0.1432	0.4587
Changes in uric acid (mg/dl)	0.1653	0.3916
Changes in eGFR (ml/min1.73m ²)	0.2478	0.1949
Changes in hematocrit (%)	-0.2654	0.1640

Changes in platelet counts ($\times 10^9/L$)	0.2316	0.2266
Changes in leptin (ng/ml)	0.4031	0.0272
Changes in HMW adiponectin ($\mu g/ml$)	0.04279	0.8288
Changes in PAP ($\mu g/ml$)	-0.412	0.0237
Changes in TAT (ng/ml)*	0.2705	0.1482

* Spearman Rank test.

BMI, body mass index; WC, waist circumference; VFA, visceral fat area; FPG, fasting plasma glucose; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RLP, remnant like lipoprotein; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, γ -glutamyltranspeptidase ;eGFR, estimated glomerular filtration rate; HMW, high-molecular weight; PAP, plasmin- $\alpha 2$ -antiplasmin complex ; TAT, thrombin-antithrombin III complex